S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:MNOV

MediciNova (MNOV) Price Target & Analyst Ratings

$2.13
+0.04 (+1.91%)
(As of 09/25/2023 ET)
Compare
Today's Range
$2.10
▼
$2.35
50-Day Range
$2.01
▼
$2.51
52-Week Range
$1.89
▼
$2.73
Volume
28,340 shs
Average Volume
17,940 shs
Market Capitalization
$104.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

MediciNova Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
9/26/22 to 9/26/23		1 Month Ago
8/27/22 to 8/27/23		3 Months Ago
6/28/22 to 6/28/23		1 Year Ago
9/26/21 to 9/26/22
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/A$6.00
Predicted UpsideN/AN/AN/A170.27% Upside
Get MediciNova Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.


MNOV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MNOV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MediciNova Stock vs. The Competition

TypeMediciNovaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside1,404.52% Upside628.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/3/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Mamtani
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
(Data available from 9/26/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MNOV Price Target - Frequently Asked Questions

What is MediciNova's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for MediciNova stock is Buy based on the current 1 buy rating for MNOVthe . Learn more on MNOV's analyst rating history.

Do Wall Street analysts like MediciNova more than its competitors?

Analysts like MediciNova more than other Medical companies. The consensus rating for MediciNova is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how MNOV compares to other companies.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MNOV) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -